BFC Planning’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
BFC Planning's DGX Position: Q3 2026 in Review
BFC Planning reduced its Quest Diagnostics (DGX) stake by 10% in Q3 2026, selling an estimated $31.9K and leaving 1,230 shares worth $287K. The position accounts for 0.01% of the portfolio, ranked #806.
BFC Planning first reported a position in DGX in Q3 2024 and has held it in 9 quarters since. The position peaked at $6.76M in Q3 2025. 978 funds tracked by Wall St. Rank hold DGX as of Q3 2026.
- BFC Planning held 1,230 shares of Quest Diagnostics worth $287K as of Q3 2026.
- BFC Planning sold 138 Quest Diagnostics shares in Q3 2026, an estimated $31.9K.
- Quest Diagnostics made up 0.01% of BFC Planning's portfolio in Q3 2026, its #806 holding.
- BFC Planning first reported a position in Quest Diagnostics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Quest Diagnostics position peaked at $6.76M in Q3 2025.
- 978 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.